

For Immediate Release**ASX/Media Release****Dimerix Investor Update**

MELBOURE, Australia; 11 April 2017: Dimerix Limited (ASX: DXB), a clinical stage biotechnology company committed to discovering and developing new therapeutic treatments identified using its proprietary screening assay, today published a copy of its latest investor presentation. The presentation highlights a number of clinical and corporate milestones including:

- Dimerix is on track to release final data for its Phase 2 Part A study in Chronic Kidney Disease in July 2017
- Interim study data released in November 2016 was positive and well received by clinicians in the sector
- The data released to date compares favourably with other larger pharmaceutical and drug research companies active in the same market sector
- The company will initiate a Phase 2 Part B study in the second half of 2017
- Dimerix believes if the Phase 2 Part A data scheduled for release in July 2017 is positive, it will be supportive of a potential licensing or partnering.

Dimerix Chief Executive Officer Kathy Harrison will make two investor presentations this week in Melbourne on Tuesday 11 April and in Sydney on Wednesday 12 April. A copy of the presentation is attached.

The company's lead compound is an innovative treatment that combines two existing pre-approved drugs and has been granted Orphan Drug Designation status in the United States.

Orphan Drug Designation gives the drug seven years exclusive marketing in the US along with a range of regulatory and financial support measures designed to expedite development.

-END-

For more information please contact:

At the company	Media (Australia)	Media (International)
Kathy Harrison Chief Executive Officer Dimerix Limited Tel: +61 419 359 149 E: kathy.harrison@dimerix.com	Andrew Geddes Tel: +61 408 677 734 E: dimerix@instinctif.com	Sue Charles/Daniel Gooch Tel: +44 (0)20 7866 7905 E: dimerix@instinctif.com

Dimerix Bioscience Pty Ltd

Dimerix Limited's wholly owned subsidiary Dimerix Bioscience Pty Ltd is a clinical-stage pharmaceutical company committed to discovering and developing new therapeutic models identified using its proprietary assay, termed Receptor-Heteromer Investigation Technology (Receptor-HIT). This assay enables the identification of pairs of receptors that function in a joint manner (interact) when ligands, small molecule drugs, peptides or antibodies, bind to them. The Receptor-HIT technology was used to identify DMX-200 in an internal drug development program, initially for the treatment of a subset of patients with chronic kidney disease. In addition to its own therapeutic

programs, the company also earns revenue by providing this technology to global pharmaceutical companies. For more information see www.dimerix.com

DMX 200

DMX-200 is being developed as an adjunct therapy, adding propagermanium to a stable dose of irbesartan. Irbesartan is an off-patent angiotensin II type I receptor blocker indicated for the treatment of hypertension and nephropathy in Type II diabetic patients. Propagermanium (PPG) is a chemokine receptor (CCR2) blocker, which has been used for the treatment of Hepatitis B in Japan and is available in the USA for its anti-inflammatory properties. DMX-200 has been shown to improve the outcome of chronic kidney disease by reducing proteinuria by more than 50 per cent in animal models⁽¹⁾.

The DMX-200 Phase II Trial

The trial is a single arm, open label study in adult patients with chronic kidney disease (with proteinuria). The primary end points are the incidence and severity of adverse events and the clinically significant changes in the safety profile of participants. The secondary end points are obtained from statistical analysis of biomarker data at each time point including change from baseline, and the proportion of responders defined as those participants achieving normalisation of proteinuria (proteinuria within normal limits) or those participants achieving a 50 per cent reduction in proteinuria.

The trial has two parts. Part A is a dose escalation trial recruiting up to 30 patients and completed enrolment at the end of November 2016. All patients recruited to the trial will be on stable irbesartan therapy, and will be treated with propagermanium dosed orally three times per day. Each patient will commence on 30mg PPG/day and the dose increased each 28 days to a maximum of 240mg/day, or until proteinuria is absent or reduced to a level the clinician considers acceptable. The Company expects to complete Part A in mid 2017.

Part B is an expansion study, in which up to 30 patients will be given the optimal dose identified from Part A.

Chronic Kidney Disease

Chronic kidney disease can result from diabetes, high blood pressure and diseases that cause inflammation specifically in the kidneys. Proteinuria is the most common manifestation of the disease. As the disease progresses it can lead to end-stage renal disease (ESRD) where the kidneys fail. The only treatment for ESRD is a kidney transplant or regular blood-cleansing treatments called dialysis. More than 26 million people suffer from the disease in the United States.

⁽¹⁾ Functional interaction between angiotensin II receptor type 1 and chemokine (C-C motif) receptor 2 with implications for chronic kidney disease. Ayoub MA, Zhang Y, Kelly RS, See HB, Johnstone EK, McCall EA, Williams JH, Kelly DJ, Pflieger KD. PLoS One. 2015 Mar 25;10(3):e0119803. doi: 10.1371/journal.pone.0119803.



A clinical phase company with a powerful drug discovery technology

Investor Update
11-12 April 2017

Some of the information in this presentation may refer to Dimerix Limited (“Dimerix” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision regarding Dimerix.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Dimerix, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Dimerix and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Dimerix is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Dimerix securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Dimerix, its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Dimerix does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

The distribution of this presentation may be restricted by law and you should observe any such restrictions.

Forward looking statements

This presentation contains certain forward looking statements that are based on the Company’s management’s beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Dimerix to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the political and economic environment in which Dimerix will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Dimerix and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

Patient Need - working to help people with chronic kidney disease (CKD), a disease that has no cure but **affects over 10% of the population**

Lead candidate DMX-200 - in **Phase 2 clinical trials** for CKD, with **data due from Part A of our two part trial in July 2017**

Market Need - *Initially* targeting patients with a specific form of kidney disease: Focal Segmental Glomerularsclerosis (FSGS), a condition with limited treatment options that are often ineffective and poorly tolerated.

- The market for FSGS treatment is estimated to be **US\$1B** in the US

Orphan Drug Designation approved by the FDA for FSGS which provides:

- **Seven years exclusive marketing** in the US
- Regulatory and financial support measures which can **accelerate development**

Patented Receptor-HIT platform technology - the powerful technology which identified DMX-200 and enables a **pipeline of opportunities**

Chronic kidney disease can lead to kidney failure, cardiovascular disease and premature death

Proteinuria, or excess protein in the urine, is the most common symptom of the disease and is indicative of decreased renal functioning

Current treatments for CKD include a cocktail of drugs such as immunosuppressants and steroids, which have high toxicity profiles and efficacy as low as 25%

- Kidney disease is a major global health problem, affecting 26 million people in the US
- The total US Medicare spending on patients with End Stage Renal Disease (ESRD) was **US \$32.8 billion** in 2014
- Due to poor efficacy and tolerability of existing treatments, a **significant response** in 25% of patients with a safe and well tolerated drug would be a **great clinical outcome**

DMX-200 – lead product candidate



Drug Combination of two approved drugs (irbesartan and propagermanium) to target inflammatory root cause of kidney disease

Planned indication(s) Initial indication FSGS, expansion to CKD

Potential advantages Safety of approved drugs with efficacy tailored by their synergistic effect

Potential market size Estimated US\$1BILLION in the US alone

Development status US FDA Orphan Drug Designation (ODD)
Phase 2A near complete, Phase 2B planned
Only single Phase 3 required under ODD
Orphan Drug designation gives seven years exclusive marketing and regulatory and financial support measures which can accelerate development

Milestones achieved

- Australian, US and Japanese patents** for lead candidate granted
- Orphan Drug Designation in the USA for FSGS
- Positive meeting with FDA – achievable path to registration
- Completed patient enrollment in Phase 2 Part A study
- Positive interim Phase 2 data
- On track to report Part A in July 2017

DMX-200 Program

Expected timeframe	Milestone
1H 2017	Manufacture of commercial propagermanium formulation
1H 2017	Commence clinical PK study with commercial formulation
June 2017	Engage with NephCure Accelerating Cures Institute
July 2017	Report Phase 2 dose escalation (Part A) – July 2017
2H 2017	Commence Phase 2 Part B
End 2018	Complete Phase 2

Other News Drivers

Milestone

Further pre-clinical studies for Non-Alcoholic Steatohepatitis (NASH)

Research collaborations and assay licensing opportunities

G-Protein Coupled Receptors (GPCRs)

- **Large family of cell surface receptors** which control most physiological process including **blood pressure, inflammation, and cellular division**
- **Over 30%** of all prescription drugs target GPCR's
- **Signalling between complexes** is essential for many cellular functions
- Drugs developed without understanding GPCR complexes may cause **unwanted and unexplained side effects**
- FDA has agreed with Dimerix that understanding GPCR complexes is a critical factor in **developing safe new drugs**

Dimerix' Receptor-HIT platform

- Patented tool that enables identification and characterisation of GPCR complexes
- Can be used to identify new uses and treatments for existing drugs, drive the discovery of new drugs, and identify entirely new therapeutic pathways

Global pharmaceutical companies need access to Dimerix's Receptor-HIT technology to develop safe new drugs

Contact

Kathy Harrison
Chief Executive Officer

+61 419 359 149

kathy.harrison@dimerix.com

Dimerix Limited

ACN 001 285 230

www.dimerix.com